HGPI’s Board Member Toshio Miyata’s commentary on pharmaceutical companies’ changing marketing strategies was featured in a Bloomberg article on Drugmakers in Japan. He pointed out that drug manufacturers are currently in a transitional period in which they are responding to changes in the medical system by diversifying their marketing strategies so that patients adhere to medication longer. He added that to achieve this end, manufacturers cannot keep on targeting sales to hospitals only, but rather should think together with different administrations and medical professionals on how to improve patients’ quality of life.

Please click here to access the article.